publication date: Dec. 19, 2010

In this issue: 

Taking on question of cost and outcomes, CMS turns to expert in cancer care quality.

Demonstration project to yield useful data, Peter Bach says.

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

Download (PDF 743KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.